Angiotensin II Type 1 Receptor Binding Molecule ATRAP as a Possible Modulator of Renal Sodium Handling and Blood

K Tamura1, H Wakui, K Azushima

  • 1Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. tamukou@med.yokohama-cu.ac.jp.

Insights

ATRAP, a novel protein, regulates angiotensin II type 1 receptor (AT1R) signaling. It promotes receptor internalization and inhibits pathological responses, offering a potential therapeutic target for hypertension and organ damage.

Area of Science:

  • Cardiovascular Research
  • Renal Physiology
  • Endocrinology

Background:

  • Renin-angiotensin system (RAS) overactivation via angiotensin II type 1 receptor (AT1R) signaling causes hypertension and organ damage.
  • Physiological AT1R signaling is crucial for normal kidney development and maintaining cardiovascular/renal homeostasis.
  • The dual role of AT1R necessitates selective modulation strategies for therapeutic benefit.

Purpose of the Study:

  • To identify novel molecules that selectively modulate AT1R signaling.
  • To investigate the functional role of a newly identified protein, ATRAP, in AT1R signaling and related pathophysiology.

Main Methods:

  • Yeast two-hybrid screening of a mouse kidney cDNA library to identify AT1R-interacting proteins.
  • Functional analysis of ATRAP in cultured cells and mouse models.
  • Assessment of ATRAP expression in various tissues, particularly the kidney.
  • Utilizing genetically engineered mice with modified ATRAP expression to study its in vivo effects.

Main Results:

  • ATRAP was identified as a direct interactor of the AT1R carboxyl-terminal cytoplasmic domain.
  • ATRAP promotes constitutive AT1R internalization in cultured cells.
  • ATRAP inhibits Ang II-mediated pathological responses in mouse renal cells.
  • Genetic modification of ATRAP influenced renal sodium handling and blood pressure regulation in response to pathological stimuli.

Conclusions:

  • ATRAP plays a significant role in regulating AT1R signaling.
  • ATRAP's ability to inhibit pathological Ang II effects suggests its therapeutic potential.
  • ATRAP is a promising target for developing new strategies to manage hypertension and related organ damage.

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.0K
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.7K
Regulation of Sodium and Potassium01:26

Regulation of Sodium and Potassium

The regulation of sodium and potassium ion concentrations in the human body is a complex process governed primarily by hormones such as aldosterone, antidiuretic hormone (ADH), and atrial natriuretic peptide (ANP).
Sodium Regulation
Sodium ions make up approximately 90% of extracellular cations, with a normal blood plasma concentration of 136–148 mEq/L. A decrease in blood volume and pressure triggers the release of renin from granular cells in the juxtaglomerular complex (JGC), primarily...
2.9K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.8K
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
4.8K
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
2.8K